NeOnc Technologies NTHI 深 滬
已收盤 08-07 16:00:00 美东时间
3.50
0.000
0.00%
華盛通- 最 高3.62
- 今 開3.50
- 成交量 5.11万股
- 最 低 3.47
- 昨 收 3.50
- 總市值 9076.15万
- 52周最高 12.99
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 3.005
- 委 比 -81.82%
- 總股本 2593.19万
- 歷史最高 25.00
- 量 比 1.21
- 振 幅 4.29%
- 歷史最低 3.005
- 每 手 1
- 風險率 2.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
NeOnc Technologies Holdings, Inc. announced the appointment of Nasim Shomali to its Board of Directors, effective July 1, 2026. Shomali brings extensive experience in corporate strategy, financial planning, and scientific expertise, particularly in CNS cancer therapies. Her addition strengthens the Board's oversight as NeOnc advances its NEO platform and clinical programs toward commercialization. Shomali's background includes advising global org...
07-27 13:00
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
NeOnc Technologies Holdings, Inc. has received detailed feedback from the FDA regarding the CMC development of NEO212, a temozolomide-perillyl alcohol conjugate. The feedback covers manufacturing, formulation, stability, and bioavailability requirements, including the transition from capsule to tablet form. NeOnc has canceled a scheduled meeting, deeming the written responses sufficient, and is integrating the feedback into its development plan. ...
07-15 13:00
NeOnc Announces Abu Dhabi DOH Grants IND Status For NEO212, Orally Administered Perillyl Alcohol-Temozolomide Carbamate Conjugate Being Developed For Patients With Aggressive Brain Tumors
Clearance enables Phase 2 evaluation of NEO212, the Company's oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose Adds an international clinical pathway alongside continuing U....
06-16 21:06
The Next Great AI Revolution May Be Drug Delivery
Artificial intelligence is revolutionizing the biotechnology sector, particularly in drug delivery systems for treating brain cancers and CNS disorders. Companies like NeOnc Technologies Holdings (NASDAQ:NTHI) are leveraging AI to overcome the blood-brain barrier, developing advanced therapies for glioblastoma and other CNS cancers. The integration of AI with precision medicine and delivery technologies is creating significant opportunities in ne...
05-29 13:05
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
BTIG Reiterates Buy on NeOnc Technologies Hldgs, Maintains $15 Price Target
BTIG analyst Thomas Shrader reiterates NeOnc Technologies Hldgs (NASDAQ:NTHI) with a Buy and maintains $15 price target.
05-26 18:26
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Maxim Group Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $20
Maxim Group analyst Jason McCarthy initiates coverage on NeOnc Technologies Hldgs (NASDAQ:NTHI) with a Buy rating and announces Price Target of $20.
05-19 02:58
NeOnc Technologies Q1 EPS $(0.38) Misses $(0.17) Estimate
NeOnc Technologies (NASDAQ:NTHI) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.17) by 123.53 percent. This is a 78.65 percent increase over losses of $(1.78) per share
05-18 21:05
